40 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
8 Jan 24
Regulation FD Disclosure
7:30am
not respond to treatments that block CGRP or its receptor Migraine is 2nd leading cause of disability worldwide and 1st among young women1 First-in-Class
8-K
EX-99.1
2py3q8 vurszjg0i
31 Jul 23
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
4:29pm
8-K
EX-99.1
tt1 9992hor
31 May 23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
7:03am
10-Q
EX-10.18
tzta3w14kwmeqqv5peh5
9 Nov 22
Quarterly report
4:19pm
10-Q
lsco9t1
9 Nov 22
Quarterly report
4:19pm
424B4
0opzp4koi256bgds2
24 Oct 22
Prospectus supplement with pricing info
9:38am
S-1/A
14cjyvbth7miwjvt0u70
20 Oct 22
IPO registration (amended)
10:00am
S-1
vmhz5lrpx6wev3gi6n
18 Oct 22
IPO registration
4:03pm
S-8
EX-4.2
6jbxj9 yjuazjq
11 Oct 22
Registration of securities for employees
4:31pm
DRS
nbqndssnl53i
11 Oct 22
Draft registration statement
12:00am
8-K
EX-3.1
8us30yix
3 Oct 22
Changes in Control of Registrant
5:21pm
10-12B/A
EX-99.1
fhzzvynquq65o66nga9
20 Sep 22
Registration of securities (amended)
6:30am
10-12B/A
EX-99.1
8wnvcsamj f8
14 Sep 22
Registration of securities (amended)
5:25pm